Table 2.
Baseline characteristics of patients and tumors
| Variables | Total (n = 35) |
|---|---|
| Gender (male) | 13 (37%) |
| Age (years) | |
| Median (min–max) | 59 (24–72) |
| Weight (kg) | |
| Median (min–max) | 67 (43-98) |
| ECOG | |
| 0 | 19 (54%) |
| 1 | 16 (46%) |
| Type of malignancy | |
| Ovary | 8 (23%) |
| Sarcoma | 5 (14%) |
| H&N cystic adenoid carcinoma | 5 (14%) |
| Colorectal | 4 (11%) |
| Breast | 4 (11%) |
| Uveal melanoma | 3 (9%) |
| Endometrial carcinoma | 1 (3%) |
| Liver | 1 (3%) |
| Lung | 1 (3%) |
| Adrenal glands | 1 (3%) |
| Thyroid | 1 (3%) |
| Pancreas | 1 (3%) |
| Prior chemotherapy | |
| Naïvea | 4 (11 %) |
| ≤2 Lines | 23 (66 %) |
| >2 Linesb | 8 (23 %) |
| Prior cisplatin | 6 (17 %) |
| Cumulated dose of prior cisplatin mg/m2 | |
| Median (min–max) | 172.5 (75; 239) |
H&N Head and neck, ECOG Eastern Cooperative Oncology Group, DL dose level, RS reverse sequence
aAll cystic adenoid carcinoma patients
bFive patients treated in DL1, 2 in DL-2, 1 in DL1RS